Tradestie Institutional Equity Comparison Engine
IMMX vs CRBP โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IMMX Overall Edge
IMMX Captures Institutional Edge (3โ0 Pillars ยท 6โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immix Biopharma, Inc. Common Stock (IMMX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, IMMX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CRBP at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, IMMX sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro) against CRBP sits in BREAKDOWN (66th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
IMMX N/M vs CRBP N/M Fwd P/E
Growth & Margin Winner
IMMX
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs -100.0%
Momentum & Technical Winner
IMMX
1Y +107.2% vs -69.5% ยท 52W Pos 35% vs 6%
Options & Structure Winner
IMMX
BREAKDOWN (17th %ile IV) vs BREAKDOWN (66th %ile IV)
IMMX
NASDAQ
Immix Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$7.48
-4.59% 1D
Market Cap
$657.1M
1M Return
-6.27%
1Y Return
+107.2%
Forward P/E
N/M
Unified AI Score
50.3 / 100
HOLD
Tech 52.0
Fund 55.0
Flow 68.0
Mom 54.0
CRBP
NASDAQ
Corbus Pharmaceuticals Holdings, Inc.
Pharmaceutical Preparations
$3.38
-0.44% 1D
Market Cap
$69.9M
1M Return
-25.33%
1Y Return
-69.51%
Forward P/E
N/M
Unified AI Score
45.0 / 100
HOLD
Tech 43.0
Fund 54.0
Flow 69.0
Mom 64.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
IMMX +107.2%
CRBP -69.51%
Spread: +176.71 pp (IMMX Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
IMMX TTM Op. Margin: 0.0%
CRBP TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IMMX vs CRBP. Trailing 12-month operating profitability (IMMX 0.0% vs CRBP 0.0%) and valuation multiples (IMMX N/M vs CRBP N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | IMMX | CRBP | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $657.1M | $69.9M | Larger Scale | IMMX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | -100.0% | Higher Growth | IMMX |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -27.0% | -131.5% | Higher ROE | IMMX |
| 52-Week Range Position Momentum | 35% ($3โ$15) | 6% ($3โ$13) | Stronger Trend | IMMX |
| Beta / 30D Volatility Risk Regime | 1.80ฮฒ ยท 84% Vol | 1.93ฮฒ ยท 121% Vol | Lower Realized Risk | IMMX |
| Unified Institutional Score Composite Signal | 50.3 / 100 (HOLD) | 45.0 / 100 (HOLD) | Higher Composite | IMMX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full IMMX vs CRBP Buy Guide
IMMX
BREAKDOWN
58d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
17th %ile
IV Regime
Compressed (<25th %ile)
CRBP
BREAKDOWN
58d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
66th %ile
IV Regime
Elevated (60thโ80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither IMMX nor CRBP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.